BioSenic S.A. (LON:0R55)

Market Cap	1.71M
Revenue (ttm)	2.43M
Net Income (ttm)	-6.31M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,691
Average Volume	2,680,458
Open	0.0045
Previous Close	0.0040
Day's Range	0.0040 - 0.0050
52-Week Range	0.0040 - 0.1890
Beta	0.22
RSI	55.67
Earnings Date	Apr 25, 2025

About BioSenic

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult ti...

• Industry: Biotechnology
• Sector: Healthcare
• Country: Belgium
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R55

Financial Performance

In 2023, BioSenic's revenue was 543,000, an increase of 104.14% compared to the previous year's 266,000. Losses were -28.78 million, 843.9% more than in 2022.

Financial numbers in EUR